ipsoprubart

all catalysts(0)

nothing on the calendar yet

News(5)

• Electra lights up with $350M IPO for pivotal immune-disease drug development
  Electra Therapeutics has exceeded its initial fundraising plans as it becomes the 26th biotech to debut publicly this year and outlines pivotal development plans for its monoclonal antibody ipsopru…
  biospace · 12d ago
• Inflammation biotech Electra charges up with $350M from upsized IPO
  Electra Therapeutics is the latest biotech to overshoot its own IPO expectations this year, with the inflammation-focused company bringing in $350 million from this morning’s Nasdaq listing.
  fiercebiotech · 13d ago
• Electra amasses $350M in biotech’s latest big IPO
  Nearly a dozen biotechnology firms have matched or raised more than $300 million in their initial public offerings in 2026, a figure not seen since new stock sales peaked in 2021, according to BioP…
  biopharma_dive · 13d ago
• Electra aims for $342M IPO to power inflammatory drug’s push through phase 3
  Electra Therapeutics is hoping to raise up to $341.9 million from an IPO in order to power the clinical development of its inflammatory disorder drug, ipsoprubart.
  fiercebiotech · 16d ago
• Electra aims to light up Nasdaq with IPO for phase 2/3 I&I push
  The 2026 IPO streak continues as Electra Therapeutics has filed to go public to support its immunology and cancer pipeline.
  fiercebiotech · 1mo ago